Amarin Corporation plc

Amarin Corporation plc is an Irish-American biopharmaceutical company dedicated to improving cardiovascular health and reducing the burden of cardiovascular disease, which remains a leading cause of death globally. Founded in 1993, the company operates with dual headquarters in Dublin, Ireland, and Bridgewater, New Jersey, USA. Its mission centers on developing and commercializing innovative therapeutics to address unmet medical needs in cardiovascular care.

The company's primary product is VASCEPA® (icosapent ethyl), a prescription-grade omega-3 fatty acid. Initially approved by the U.S. Food and Drug Administration (FDA) in 2012 for severe hypertriglyceridemia, its indication was expanded in 2019 to reduce cardiovascular risk in adult patients with elevated triglycerides and other risk factors. Marketed as VAZKEPA in Europe, this product forms the core of Amarin's efforts to provide evidence-based therapies for cardiovascular risk reduction.

Under the leadership of President and CEO Aaron Berg, appointed in June 2024, Amarin is navigating a dynamic market landscape. The company reported a 7.4% year-over-year increase in total net revenue for Q1 2026, reaching $45.1 million, alongside a 31% reduction in operating expenses due to restructuring efforts. Amarin narrowed its operating loss and generated positive cash flow for the second consecutive quarter, ending Q1 2026 with $307.8 million in cash and investments. Facing generic competition in the U.S., Amarin has strategically pivoted towards global expansion, notably through a partnership with Recordati for the European commercialization of VAZKEPA, which has launched in 10 countries. The company anticipates being cash-flow positive for the full year 2026.

Latest updates

Amarin's Partnered Model Drives Q1 Revenue, Eyes European Expansion

Event summary

  • Amarin reported Q1 2026 revenue of $45.1 million, a 7% increase year-over-year.
  • European product revenue grew, driven by Recordati's commercial efforts, with sales beginning in 10 countries.
  • U.S. VASCEPA prescriptions rose 17% in Q1 2026, despite generic competition.
  • The company achieved positive cash flow for the second consecutive quarter and expects full-year positive cash flow.

The big picture

Amarin's strategic shift towards partnered international distribution appears to be yielding early results, offsetting the ongoing challenges in the U.S. market. The updated cardiovascular guidelines represent a potential tailwind, but the company's ability to capitalize on this opportunity will depend on effective execution and navigating evolving payer dynamics. The company's focus on cost optimization and cash flow generation is crucial for long-term sustainability.

What we're watching

European Adoption
The success of the Recordati partnership hinges on expanding distribution across Europe, and the pace of this rollout will dictate future revenue growth.
Guideline Impact
The updated ACC/AHA guidelines could significantly broaden the patient pool for IPE, but adoption will depend on physician acceptance and payer coverage.
U.S. Resilience
Maintaining VASCEPA's market share in the face of generic erosion will require continued innovation and strategic commercialization efforts.
CID: 1900